Clinical Trial Update: Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results for MMH-MAP in cognitive disorders have been posted, detailing efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders

Drugs mentioned

• MMH-MAP

Snippet

Sponsor: Materia Medica Holding | Conditions: Cognitive Disorders | Phase 3 | Status: COMPLETED | Results posted: 2024-10-28